IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
IMUNON (NASDAQ: IMNN), a clinical-stage biotechnology company, has scheduled its second quarter 2025 financial results conference call for August 5, 2025, at 11:00 a.m. ET. The company will discuss Q2 2025 financial performance and provide updates on IMNN-001, their DNA-based interleukin-12 immunotherapy currently in Phase 3 clinical trials for advanced ovarian cancer.
Investors can access the call via toll-free numbers or join through a live webcast. A replay will be available until August 19, 2025, through multiple channels including toll-free numbers and a 90-day audio replay on the company's website.
IMUNON (NASDAQ: IMNN), un'azienda biotecnologica in fase clinica, ha programmato la conference call per la presentazione dei risultati finanziari del secondo trimestre 2025 per il 5 agosto 2025 alle 11:00 ET. La società discuterà le performance finanziarie del Q2 2025 e fornirà aggiornamenti su IMNN-001, la loro immunoterapia a base di DNA dell'interleuchina-12 attualmente in trial clinici di Fase 3 per il tumore ovarico avanzato.
Gli investitori potranno partecipare alla chiamata tramite numeri verdi o seguire la diretta streaming. Una registrazione sarà disponibile fino al 19 agosto 2025, accessibile tramite diversi canali, inclusi numeri verdi e una replica audio di 90 giorni sul sito web dell'azienda.
IMUNON (NASDAQ: IMNN), una empresa biotecnológica en fase clínica, ha programado su llamada para presentar los resultados financieros del segundo trimestre de 2025 para el 5 de agosto de 2025 a las 11:00 a.m. ET. La compañía discutirá el desempeño financiero del Q2 2025 y ofrecerá actualizaciones sobre IMNN-001, su inmunoterapia basada en ADN de interleucina-12 actualmente en ensayos clínicos de Fase 3 para cáncer de ovario avanzado.
Los inversores podrán acceder a la llamada mediante números gratuitos o unirse a través de una transmisión en vivo. Una repetición estará disponible hasta el 19 de agosto de 2025, a través de múltiples canales, incluyendo números gratuitos y una reproducción de audio de 90 días en el sitio web de la compañía.
IMUNON (NASDAQ: IMNN)은 임상 단계 바이오테크 기업으로, 2025년 2분기 재무 실적 컨퍼런스 콜을 2025년 8월 5일 오전 11시(동부시간)에 예정하고 있습니다. 회사는 2025년 2분기 재무 성과를 논의하고, 현재 3상 임상시험 중인 고급 난소암 치료용 DNA 기반 인터루킨-12 면역치료제 IMNN-001에 대한 최신 정보를 제공할 예정입니다.
투자자들은 무료 전화번호를 통해 콜에 접속하거나 라이브 웹캐스트를 통해 참여할 수 있습니다. 녹음본은 2025년 8월 19일까지 무료 전화번호 및 회사 웹사이트에서 90일간 오디오 재생을 통해 제공됩니다.
IMUNON (NASDAQ: IMNN), une société biotechnologique en phase clinique, a programmé sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2025 pour le 5 août 2025 à 11h00 ET. La société discutera de la performance financière du T2 2025 et fournira des mises à jour sur IMNN-001, leur immunothérapie à base d'ADN interleukine-12 actuellement en essais cliniques de phase 3 pour le cancer de l'ovaire avancé.
Les investisseurs peuvent accéder à l'appel via des numéros gratuits ou se joindre via un webcast en direct. Une rediffusion sera disponible jusqu'au 19 août 2025 via plusieurs canaux, y compris des numéros gratuits et une relecture audio de 90 jours sur le site web de la société.
IMUNON (NASDAQ: IMNN), ein biotechnologisches Unternehmen in der klinischen Phase, hat seine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2025 für den 5. August 2025 um 11:00 Uhr ET angesetzt. Das Unternehmen wird die finanzielle Leistung des Q2 2025 besprechen und Updates zu IMNN-001, ihrer DNA-basierten Interleukin-12-Immuntherapie, die sich derzeit in Phase-3-Studien bei fortgeschrittenem Eierstockkrebs befindet, geben.
Investoren können über gebührenfreie Nummern teilnehmen oder per Live-Webcast zuschalten. Eine Wiederholung steht bis zum 19. August 2025 über verschiedene Kanäle, einschließlich gebührenfreier Nummern und einer 90-tägigen Audio-Wiedergabe auf der Website des Unternehmens, zur Verfügung.
- None.
- None.
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Tuesday, August 5, 2025 to discuss financial results for the second quarter ended June 30, 2025 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing the IMNN-001 development program in a Phase 3 clinical trial in advanced ovarian cancer.
To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Second Quarter 2025 Financial Results Call. A live webcast of the call will also be available here.
The call will be archived for replay until August 19, 2025, and can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International Toll) using replay access code 9465184. An audio replay of the call will also be available here for 90 days.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). The first trial site was initiated for the Company’s Phase 3 pivotal study, called OVATION 3, in the second quarter of 2025. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), and include statements regarding our planned stock split. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to the reverse stock split having the desired effect, our ability to regain compliance with Nasdaq’s listing requirements, the potential de-listing of our shares on Nasdaq, risks and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| CG Life | ICR Healthcare |
| Jenna Urban | Peter Vozzo |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
# # #
FAQ
When is IMUNON's (IMNN) Q2 2025 earnings call scheduled?
What is IMNN-001 and what stage of development is it in?
How can investors access IMUNON's Q2 2025 earnings call?
Until when will IMUNON's Q2 2025 earnings call replay be available?
